Case No. | Tumour content | KRAS Ion NGS | KRAS IDYLLA | NRAS Ion NGS | NRAS IDYLLA | BRAF Ion NGS | BRAF IDYLLA |
---|---|---|---|---|---|---|---|
1 | 80% | WT | WT | G12D | G12D | WT | WT |
2 | 70% | WT | WT | G12D | G12D | WT | WT |
3 | 70% | WT | WT | WT | WT | V600E | V600D/E |
4 | 70% | WT | WT | WT | WT | V600E | V600D/E |
5 | 50% | WT | WT | WT | WT | V600E | V600D/E |
6 | 50% | WT | WT | WT | WT | V600E | V600D/E |
7 | 50% | WT | WT | WT | WT | V600E | V600D/E |
8 | 70% | WT | WT | Q61R | Q61R | WT | WT |
9 | 50% | WT | WT | G12D | G12D | WT | WT |
10 | 70% | G12D | G12D | WT | WT | WT | WT |
11 | 50% | G12D | G12D | WT | WT | WT | WT |
12 | 50% | G12V | G12V | WT | Q61L | WT | WT |
13 | 60% | G12D | G12D | WT | WT | WT | WT |
14 | 60% | N/A | Not tested | WT | WT | V600E | V600D/E |
15 | 70% | N/A | Not tested | WT | Failed | V600E | Failed |
16 | 30% | N/A | Not tested | WT | WT | V600E | V600D/E |
17 | 50% | N/A | Not tested | WT | WT | V600E | V600D/E |
18 | 50% | N/A | Not tested | G12C | G12C | WT | WT |
19 | 80% | Q61K | Q61K | N/A | Not tested | N/A | Not tested |
20 | 50% | G12V | G12V | N/A | Not tested | N/A | Not tested |
21 | 50% | G12D | G12D | N/A | Not tested | N/A | Not tested |
22 | 70% | G12D | G12D | N/A | Not tested | N/A | Not tested |
23 | 50% | G12C | G12C | N/A | Not tested | N/A | Not tested |
The Ion AmpliSeq Cancer Hotspot Panel was compared with the Idylla NRAS-BRAF-EGFRS492R Mutation Assay and the Iydlla KRAS Mutation Test. Not all cases were tested with both Idylla assays. Tumour percentage given is the minimum estimate.
NGS, next-generation sequencing; WT, wild type.